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Abstract
Background: Methicillin resistant Staphylococcus aureus (MRSA) are often resistant to multiple classes of antibiotics.
The research objectives of this systematic review were to evaluate the clinical effectiveness of polymerase chain
reaction (PCR) versus chromogenic agar for MRSA screening, and PCR versus no screening for several clinical
outcomes, including MRSA colonization and infection rates.
Methods: An electronic literature search was conducted on studies evaluating polymerase chain reaction
techniques and methicillin (also spelled meticillin) resistant Staphylococcus aureus that were published from 1993
onwards using Medline, Medline In-Process & Other Non-Indexed Citations, BIOSIS Previews, and EMBASE. Due to
the presence of heterogeneity in the selected studies, the clinical findings of individual studies were described.
Results: Nine studies that compared screening for MRSA using PCR versus screening using chromogenic agar in a
hospital setting, and two studies that compared screening using PCR with no or targeted screening were identified.
Some studies found lower MRSA colonization and acquisition, infection, and transmission rates in screening with PCR
versus screening with chromogenic agar, and the turnaround time for screening test results was lower for PCR. One
study reported a lower number of unnecessary isolation days with screening using PCR versus screening with
chromogenic agar, but the proportion of patients isolated was similar between both groups. The turnaround time for
test results and number of isolation days were lower for PCR versus chromogenic agar for MRSA screening.
Conclusions: The use of PCR for MRSA screening demonstrated a lower turnaround time and number of isolation days
compared with chromogenic agar. Given the mixed quality and number of studies (11 studies), gaps remain in the
published literature and the evidence remains insufficient. In addition to screening, factors such as the number of
contacts between healthcare workers and patients, number of patients attended by one healthcare worker per day,
probability of colonization among healthcare workers, and MRSA status of hospital shared equipment and hospital
environment must be considered to control the transmission of MRSA in a hospital setting.
Background
Methicillin resistant Staphylococcus aureus (MRSA) are
often resistant to multiple classes of antibiotics. In hos-
pitals, transmission occurs from a colonized or an
infected individual to other s ,m a i n l yv i at h eh a n d so f
transiently-colonized healthcare workers [1]. MRSA has
been associated with many infection sites including
bones and joints, lungs, and the urinary tract [2]. Bacter-
emia is common, possibly leading to endocarditis and
osteomyelitis [2]. Hospital-acquired MRSA is typically
resistant to classes of antimicrobials other than b-lac-
tams [3].
A national MRSA prevalence study by the Association
for Professionals in Infection Control and Epidemiology,
Inc., conducted in 2006, determined that 46 out of every
1,000 patients in the United States were either MRSA
colonized or infected [4]. The incidence of MRSA in 47
sentinel, geographically-dispersed Canadian hospitals par-
ticipating in the Canadian Nosocomial Infection Surveil-
lance Program in 2007 was 8.62 cases (2.57 infection and
5.87 colonization) per 1,000 patient admissions and 11.63
cases (3.47 infection and 7.92 colonization) per 10,000
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bloodstream infection per 100,000 patient days ranged
from 0.2 in Sweden to 2.4 in Portugal [6].
A c t i v es u r v e i l l a n c eo fM R S Ai sp a r to fa ni n f e c t i o n
control and preventive measure that also includes isola-
tion, cohorting and decolonization. The effectiveness of
these practices to reduce the risk of MRSA transmission
in a hospital setting remains controversial [7,8].
The polymerase chain reaction (PCR) is a molecular
technique in which enzymatic replication is used to
amplify a short sequence of DNA. Because it is used to
reproduce selected sections of DNA, the presence of
MRSA is more rapidly and easily detected (up to five
hours) compared with culture-based methods, which can
take one to two days [9]. PCR is used to identify the SCC
mec cassette that contains the mecA gene and orfX, an
opening frame distinctive to Staphylococcous aureus
[10,11]. In the US and Canada, there are three automated
commercially available PCR systems that are approved for
detection of MRSA: BD GeneOhm MRSA Assay, Xpert
MRSA Assay, and Roche LightCycler MRSA Advanced.
They are qualitative, in vitro diagnostic tests designed for
direct detection of MRSA nasal colonization [12-15].
The primary research objective of this systematic review
was to evaluate the clinical effectiveness of screening with
PCR versus screening with chromogenic agar or no
screening with regards to MRSA colonization, acquisition,
transmission and infection rates, the turnaround time to
report the test results and number of isolation days and
inappropriate open days (patients for whom isolation pre-
cautions were not implemented and who were MRSA
positive on admission) in a hospital setting.
Methods
Literature search strategy
Peer reviewed literature searches were conducted for the
clinical review. The following bibliographic databases
were searched through the OvidSP interface: Medline,
Medline In-Process & Other Non-Indexed Citations,
EMBASE, Biosis Previews, and CINAHL. Parallel
searches were run in PubMed and the Cochrane Library.
The search strategy comprised both controlled vocabu-
lary, such as the National Library of Medicine’sM e S H
(Medical Subject Headings), and keywords. The main
search concepts were methicillin (also spelled meticillin)
resistant Staphylococcus aureus, and polymerase chain
reaction techniques. No methodological filters were
applied. Searches were restricted to articles published
from January 1993 until May 2011 to focus on current
PCR techniques.
Selection criteria
Studies were eligible if they compared MRSA screening
using one of the commercially available PCR tests, BD
GeneOhm MRSA, Xpert MRSA and RocheLightCycler
MRSA Advanced, versus screening with chromogenic
agar or no screening in adult patients. The types of out-
comes measured were MRSA colonization and acquisi-
tion rates, bacteremia and other infection rates (for
example, wound, surgical site) caused by MRSA, MRSA
transmission rate; turnaround time from admission to
results telephoned, and number of isolation and inap-
propriate open days. Studies with no comparator or stu-
dies that were not conducted in a hospital setting were
excluded.
Selection and data extraction
Two reviewers (JP, SC) scanned the titles and abstracts
that were identified during the literature search and
applied the selection criteria. Data from each included
trial were extracted by two reviewers (JP, SC) working
independently with a structured form, and were verified
for discrepancies and tabulated. Any differences were
discussed and resolved by consensus. When an agree-
ment could not be achieved, a third reviewer cast a
deciding vote.
Quality assessment
A quality assessment of randomized and non-rando-
mized studies that measured the clinical effectiveness of
MRSA screening was assessed independently by two
reviewers (JP, SC), using a modified checklist by Downs
and Black [16]. One item, source of funding for the
study, was added to the checklist. A critical appraisal of
reporting, external and internal validity, and power for
each included selected study was conducted. Any differ-
ences were discussed and resolved by consensus. When
an agreement could not be achieved, a third reviewer
cast a deciding vote.
Data analysis methods
Because there was great variation in the control arms,
study design, and reporting of clinical findings for each
study, a formal meta-analysis was not done. Instead, the
studies were described individually.
Results
Quantity of research available
The literature search identified 2,262 citations. From
these, 336 potentially relevant full-text articles were
retrieved for further scrutiny. Eleven studies were
selected for inclusion. Studies were excluded if the study
participants were not limited to hospitalized patients,
used an inappropriate intervention or comparators, or no
comparators, were not performed in a hospital setting,
did not examine hospital-acquired MRSA or measured
the wrong outcomes. The PRISMA flowchart in Figure 1
details the process of the study selection.
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The study characteristics appear in Table 1.
Study Design
A prospective cohort design was used in eight studies,
[17-24] and three studies were cluster crossover trials
[25-27].
Patient Population
Studies were conducted in surgical,[18-20,22,25,26]
elderly care,[17,27] oncology,[27] and medical-cardiol-
ogy,[23,26] wards in a hospital setting. In addition to
the cardiology ward, Wassenberg et al. included patients
admitted to intensive care units and to internal medi-
cine, surgical, pediatrics, and neurology wards [23].
Hombach et al. did not specify the hospital wards their
study [23]. The sample size ranged from 246[17] to
153,511 patients [21].
Collection and Anatomical Site of Specimen
Four studies used Copan swabs for specimen collection
and transport [17,18,24,26]. One study used the BBL
CultureSwab [19]. The remaining studies did not specify
the type of specimen transport system used. In all stu-
dies that reported the details of the specimen transport
s y s t e m ,l i q u i dS t u a r tm e d i u mw a su s e d .S i xs t u d i e s
examined nasal specimens only [23]. In addition to
nares, specimens were collected from the throat, axillae,
perineum or groin in five other trials [18,23,24,26,27].
Intervention and comparators
BD GeneOhmMRSA was compared with chromogenic
agar in seven studies,[19-22,25-27] and Xpert MRSA
was assessed in two other studies [17,18]. The clinical
effectiveness of BD GeneOhmMRSA and Xpert MRSA
was assessed in two studies [23,24]. Studies that evalu-
ated LightCycler MRSA Advanced did not meet the
selection criteria. Five studies compared the clinical
effectiveness of PCR with chromogenic agar (MRSA ID,
Biomerieux, Marcy l’Étoile, France) [23-26]. Chromo-
genic agar MRSA Select (Bio-Rad, Marne La Coquette,
France) was used in two studies;[17,18] Jeyaratnam et al.
included MRSA Chromoagar, Oxoid, Basingstole, UK)
[27] as the comparator, and Synder et al. used BBL
CHROMagar MRSA medium (C-MRSA)[19]. Two stu-
dies did not identify the test method used during speci-
fic phases [21,22]. As part of the preparation process,
the specimens were broth-enriched in four studies
[19,22,24,27].
Quality assessment
The methodological quality of the studies in this sys-
tematic review was mixed. The assessment indicated
that the weakest area was internal validity related to
confounding. In particular, it was unclear whether
patients were randomized to the intervention or control
arms,[26] and if potential confounders were investigated,
[21,26] and there was a lack of reporting about patients
who were lost to follow-up [21,26]. In Pofahl et al.’s and
Robicsek et al.’s studies, the intervention and control
groups were studied during different phases over a per-
iod of approximately three years to seven years [20,21].
This study design may lead to potential biases because
several factors that were related to investigator knowl-
edge (the investigator is not blinded from the outcome
variable), timing (interventions at different study phases
over a long time period may lead to changes in beha-
viour) and proficiency (different resources or procedures
may be used at different times) may affect the estimated
comparisons of the clinical outcomes [21]. One study
explicitly met the criteria for internal validity [27].
Patients were randomized, and there were adjustments
for confounding, such as standard errors for correlation
within wards. A restricted primary outcome analysis was
conducted where all patients with any MRSA positive
culture specimen within three months before admission,
and those with MRSA positive discharge screens taken
within 48 hours of negative admission swab were
excluded. Patients who were MRSA positive on admis-
sion and those lost to follow-up were included in
resource analysis [27].
2,262 citations identified from 
electronic search and screened
336 potentially relevant 
reports retrieved for scrutiny 
(full text, if available)
1,926 citations 
ldd
0 potentially 
relevant reports 
retrieved from other 
sources 
336 potentially 
relevant reports
325 reports excluded:
• irrelevant study population 
(16)
• irrelevant comparator (97)
• irrelevant interventions (48)
• irrelevant outcomes (31)
• other (e.g., abstract only, 
review, duplicate, etc.) 
(133)
11 studies included 
in systematic review
Figure 1 Flowchart of Included Studies for Clinical Review.
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First author;
country; year
Number of
centres; sponsor
Study design;
swab; anatomical
site of specimen
Number of patients and patient
characteristics;
Study duration Description of comparison arms
Hombach;
Switzerland; 2010
[24]
1 hospital; NR Prospective cohort
study; Copan
®
swab; nose and
groin
425 patients who i) arrived from or travelled to
countries with known high rates of prevalence;
ii) were transferred from LTC facilities; iii) were
transferred from another health care facility; iv)
were hospitalized within the previous 6
months; or v) had a history of MRSA
colonization or infection
August 2007 to August 2008 Control arm: Broth-enriched (1 ml; tryptic soy
broth [Becton Dickinson, Franklin Lakes, NJ,
USA] supplemented with 7.5% NaCl and
incubated for 24 h in ambient air 35°C. Swabs
were subcultured on chromogenic agar
medium (ChromIDMRSa agar; bioMérieux,
Marcy l’Etoile, France) in ambient air 35°C
Intervention arm 1: BD GeneOhm MRSA assay
(BD, san Diego, CA, USA) performed with a
SmartCycler II (Cepheid, Sunnyvale, CA, USA)
according to manufacturer’s instructions
Intervention arm 2: Xpert MRSA assay (Cepheid,
Inc., Sunnyvale, CA, USA)
Wassenberg;
Netherlands; 2010
[23]
14 hospitals;
government and
industry
Prospective cohort
study; swab not
specified; anterior
nares, throat and
perineum
1,764 patients admitted to internal medicine,
paediatrics, cardiology, neurology, and other
(not specified) wards were included in the
study. Patients admitted to the ICU were
excluded from the BD GeneOhm MRSA study.
December 2005 to June 2008 Control arm: Conventional culture (not
specified)
Intervention arm 1: BD GeneOhm MRSA PCR
(BD Diagnostics, San Diego, CA, USA) run on
the Cepheid Smart Cycler.
Intervention arm 2: Xpert MRSA assay (Cepheid,
Sunnyvale, CA, USA)
Intervention arm 3: Chromogenic agar (MRSA-
ID, bioMérieux, Marcy-l’Étoile, France)
Laurent; Belgium;
2010[17]
32-bed geriatric
ward of a 390-bed
tertiary-care hospital;
industry
Prospective cohort
study; Copan
®
swab; nares
246 patients admitted to the geriatric ward,
who presented at least one risk factor for
MRSA colonization (i.e., antimicrobial therapy
within the last 3 months, transfer from another
hospital or from a nursing home,
hospitalization in the previous year, presence of
chronic wounds, past history of MRSA carriage
or infection)
November 2007 to July 2008 Control arm: Chromogenic agar (CAM) MRSA
Select (Bio-Rad, Marne La Coquette, France)
Intervention arm: Xpert MRSA assay on a
GeneExpert DX system, version 1.2 (Cepheid)
according to manufacturer’s instructions
Creamer; Ireland;
2010[18]
1 acute care adult
tertiary care referral
hospital of 700
beds; government
and industry
Prospective cohort
study; Copan
®
swab; nares and
groin
567 patients who were previously MRSA-
positive, transferred either internally or
externally, had been hospitalized during the
last 18 months and/or admitted to an ICU in
the past 3 months. Patients with chronic
wounds, underlying skin conditions, urinary
catheters, stomas, or intravascular devices other
than peripheral intravenous catheters were also
included.
September 2008 to February 2009
during 3 time periods:
Period 1: 5-week observational
period where at-risk patients for
MRSA colonization were screened
only with culture
Period 2: 10-week period where
screening specimens were
processed by culture and by a
rapid PCR assay
Period 3: 5–week observational
period where only culture was
used for MRSA screening
During the study period, patients
in the emergency department,
medical wards and surgical wards
were screened.
Periods 1 and 3: Patients were screened with
direct culture on MRSASelect chromogenic agar
plates (Bio-Rad Life Science Group)
Period 2: Xpert MRSA real-time PCR assay on
the GeneXpert platform (Cepheid)
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Snyder; US; 2010
[19]
1 tertiary teaching
hospital of 350
beds; none
Prospective cohort
study; BBL
CultureSwab; nares
Patients in ICU units, such as medical, surgical,
neurological and cardiac
Number of patients = NR
Study duration = NR Control arm: BBL CHROMagar MRSA medium
(C-MRSA) and swab was then inoculated into
enrichment broth, BBL tryptic soy broth with
6.5% NaCl (BD Diagnostics, Sparks, MD, USA)
Intervention arm: BD GeneOhm MRSA real-time
PCR system (BD Diagnostics-GeneOhm, San
Diego, CA, USA)
Pofahl; US; 2009
[20]
1 tertiary care
hospital of 761
beds; none
Prospective cohort
study; swab not
specified; nares
5,094 patients undergoing surgical infection
prevention project procedures
Targeted screening = 56,835 operations
Universal screening = 35,778 operations
Period 1 (targeted screening) =
January 1, 2004
Period 2 (universal screening) =
February 15, 2007
Note: The end date of each study
period was not reported.
Period 1: High-risk patients for MRSA carriage
were screened on admission and placed in
contact precaution prior to test results
notification. MRSA screening test method for
this phase was not specified.
Period 2: All admissions were screened for
MRSA using BD GeneOhm, and patients were
placed in contact precaution prior to
notification of test results. Positive test results
were confirmed with culture-based methods.
Hardy; UK; 2009
[25]
1 teaching hospital
of 1,200 beds;
industry
Prospective, cluster
two-period cross-
over trial; swab not
specified; nares
10,934 patients admitted to one of the study
wards [general surgery (2), thoracic (1), ear,
nose and throat (1), trauma and orthopedic (2)
and urology (1)] for > 24 hours = 13,952
patient ward episodes (i.e., each separate ward
admission for the same patient was counted.
1,270 (9.1%) PWE were excluded from the
study analysis. [32 (0.2%) had no sample taken
at admission and 1,238 (8.8%) had no sample
taken at all]
January 2005 to April 2007 (2-
month pilot period, two 8-month
crossover periods and 1-month
follow-up of study patients)
Control arm: chromogenic agar (MRSA ID;
Biomerieux, Marcy, l’Étoile, France)
Intervention arm: BD GeneOhm MRSA (BD
Diagnostics-GeneOhm, San Diego, CA, USA)
Where discrepant results occurred between
chromogenic agar and PCR, samples were
placed into broth enrichment and then sub-
cultured onto chromogenic media.
Aldeyab, UK, 2009
[26]
1 hospital; none Cluster crossover
trial; Copan
swabs
®; nares,
axillae and groin
Patients in medical⁄cardiology (2) and surgical
(2) wards were studied.
Number of patients = NR
Phase 1: October 2006 to January
2007
Phase 2: February 2007 to May
2007
2-week washout period occurred
between phases
Phase 1: Patients in surgical ward were
screened using IDI-MRSA assay (BD GeneOhm,
Oxford, UK) and patients in the medical⁄
oncology ward were screened using
chromogenic agar (MRSA-ID)*
Phase 2: Both wards switched screening
methods*
Robicsek; US; 2008
[21]
3-hospital
organization;
honoraria from
industry
Prospective cohort
study; swab not
specified; nares
No active surveillance (i.e., no screening) =
39,521
ICU surveillance = 40,392
Universal surveillance = 73,427
August 2003 to April 2007 Period 1: Routine surveillance of MRSA did not
occur
Period 2: Nasal surveillance for MRSA
colonization for ICU admissions using an in-
house screening method**
Period 3: Nasal surveillance for MRSA
colonization for all hospital admissions on day
one using BD GeneOhm
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Jeyaratnam; UK;
2008[27]
1 hospital (2 sites);
government
Cluster randomized
crossover trial;
swab not specified;
nares, axillae and
groin
9,608 patients were admitted to study wards:
[surgical (6), elderly care (2), and oncology (2)].
(6,888 patients had full data and were eligible)
January 2006 to March 2007 (3-
month baseline period, 5-month
intervention period, 1-month
washout period, and 5-month
intervention period)
Control arm: swabs were taken on admission
for culture only
Intervention arm: one swab used BD GeneOhm
MRSA Assay and another swab used culture
Culture method: swabs were cultured in a
selective broth and, after May 2006, were
combined with Chromagar (Oxoid, Basingstoke,
UK)
Jog; UK; 2008[22] 1 hospital; none Prospective, cohort
study; swab not
specified; nares
1,462 patients admitted for cardiac surgery October 2004 to September 2006 Control arm: chromID MRSA agar (bioMérieux,
Marcy l’Étoile, France) and enrichment culture
was performed after the assay procedure. For
the broth enrichment, the swabs were
incubated overnight in tryptic soy broth
containing 6.5% NaCl at 35°C before subculture
onto chromID MRSA and 5% sheep blood agar
(Oxoid, Basingstoke, UK) with a 1 μg oxacillin
disc.
Intervention arm: Gene Ohm MRSA Test
(Becton Dickinson, New Jersey, USA) run on
the Cepheid Smart Cycler.
ICU = Intensive care unit; LTC = Long-term care; NR = Not reported
*All swabs were also inoculated into Robertson’s cooked meat broth, incubated at 35°C for 18-24 h and were then subcultured onto MRSA-ID.
**Only the universal and no active surveillance arms were examined based on the selection criteria for the clinical review.
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3Data analyses and synthesis
The clinical findings that were associated with MRSA
colonization, infection and transmission rates, as well as
turnaround times and isolation days for screening using
PCR compared with screening using chromogenic agar
are reported in Table 2.
MRSA colonization and acquisition
Three studies compared the MRSA colonization and
acquisition rates between screening with PCR (BD Gen-
eOhm) and screening with chromogenic agar [25-27].
The overall results suggested that patients screened
using PCR are less likely to transmit MRSA in a hospital
setting compared with patients screened using chromo-
genic agar.
Hardy et al. measured the acquisition rate as the ratio
of the number of patients acquiring MRSA in one study
ward to the number of MRSA positive patients on
admission [25]. Patients in the chromogenic agar arm
were 1.49 times more likely to acquire MRSA compared
with those in the PCR arm. The study also found the
MRSA incidence rates per 100 bed-days to be lower for
patients who were screened using PCR compared with
patients who were screened using chromogenic agar
(0.286 versus 0.410) [25].
Aldeyab et al. reported a lower MRSA incidence rate
per 1,000 bed-days for screening with PCR versus
screening with chromogenic agar among patients in the
surgical ward (20.0 versus 22.1). The difference was
more pronounced in the medical-cardiology ward (11.8
versus 20.3) [26].
Jeyaratnam et al. found fewer patients acquired MRSA
(n = 99; 2.8%) (95% CI: 2.26 to 3.34) when PCR screen-
ing was used compared with screening using chromo-
genic agar (n = 108; 3.2%) (95% CI: 2.6 to 3.79) [27].
The MRSA unadjusted and adjusted acquisition rates
were similar between both groups (unadjusted odds
ratios = 0.88; adjusted odds ratio = 0.91) [27]. In both
instances, the 95% confidence intervals (CIs) were wide,
so the results must be interpreted with caution.
MRSA infection
Jeyaratnam et al. found MRSA wound infections in 21
patients who were screened using PCR (BD GeneOhm)
versus 22 patients who were screened using chromo-
genic agar [odds ratio (OR): 0.91; 95% CI: 0.48 to 1.7)]
[27]. In this study, one MRSA bacteremia case was
found in the PCR arm and two were found in the chro-
mogenic agar arm (OR: 0.49; 95% CI: 0.01 to 9.1). The
results must be interpreted with great caution given the
wide CIs.
Two studies found lower rates of MRSA surgical site
infections (SSIs) with universal screening using PCR (BD
GeneOhm) versus no screening [20,22]. Pofahl et al. also
reported a decrease in the proportion of MRSA SSIs
from 11.6% in the no screening group compared with
7.1% in the universal screening group [20]. The reduction
of MRSA SSIs was more significant in patients under-
going orthopedic surgery (p = 0.04) compared with
patients undergoing cardiac surgery or a hysterectomy.
Robiscek et al. presented the absolute difference in
infections per 10,000 patient-days between no screening
and universal surveillance with PCR of -5.0 (95% CI:
-6.6 to -3.5)] [21]. The study also found a decrease in
the prevalence density of MRSA bacteremia from base-
line to universal surveillance (absolute reduction: -1.1
per 10,000 patient-days; 95% CI: -1.9 to -0.2) [21].
MRSA transmission
Jeyaratnam et al. reported a lower MRSA transmission
rate among patients who were screened using PCR
(0.33) versus patients who were screened using chromo-
genic agar (0.36) (incidence rate ratio: 0.85; 95% CI: 0.64
to 1.12) [27]. Since the 95% CI crosses the value of 1,
the results are not statistically significant.
Turnaround time from admission to results reported
The major promise of PCR is the lower turnaround time
from admission to results reported. All studies reported
a lower turnaround time for screening with PCR (BD
GeneOhm MRSA) versus screening with chromogenic
agar. The mean turnaround time ranged from 13.2
hours to 21.6 hours with PCR (BD GeneOhm) versus
46.2 hours to 79.2 hours using chromogenic agar, across
all studies [19,25-27].
The median turnaround time was less for screening
using Xpert MRSA versus screening using chromogenic
agar for definitive test results (1.9 hours versus 66.9
hours) in one study[17] and the mean overall turn-
around time for Xpert MRSA was 17.1 hours compared
with 53.9 hours with chromogenic agar in another study
[18]. The median and mean turnaround times were cal-
culated differently in each study, which may partially
explain the discrepancy in the results. For instance,
Creamer et al. reported a mean turnaround time of 2.6
hours for screening with PCR if the time spent on speci-
men collection to the arrival of the specimen in the
laboratory was not considered [18].
As seen in Table 2, Wassenburg et al. and Hombach et
al. reported the shortest turnaround times from the speci-
men collection to a definite a test result with XpertMRSA
versus BD GeneOhm MRSA and chromogenic agar
[23,24]. In one study, the arrival of the specimens were
longest for BD GeneOhm MRSA compared with the other
test. The authors attributed the longer transportation of
specimens to a laboratory with BD GeneOhm MRSA ver-
sus the other tests to a learning effect but did not provide
further details [23,24]. Moreover, fewer hospitals in the
Polisena et al. BMC Infectious Diseases 2011, 11:336
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First author Outcome Measurement Main study findings
MRSA colonization
Hardy[25] PCR Chromogenic
agar
PWE of MRSA positive on admission 266 (4.4%) 187 (2.8%)
PWE of acquired MRSA 111 (1.9%) 157 (2.4%)
Rate ratio of MRSA acquisition rate 1.49; 95% CI: 1.115-2.0003
Aldeyab[26] PCR Chromogenic
agar
1,000 bed-days in surgical ward 20.0 22.1
1,000 bed-days in medical/cardiology ward 11.8 20.3
Average monthly cases of MRSA⁄100 patient-admissions in surgical ward 6.8 (range: 3.6 to 15) 7.3 (range: 5.4 to
9.3)
Average monthly cases of MRSA⁄100 patient-admissions in medical/
cardiology ward
9.0 (range: 3.3 to 12.2) 7.3 (range: 6.1 to
9.8)
Jeyaratnam[27] PCR Chromogenic
agar
Proportion of patients who acquired MRSA 2.8% (n = 99) (95% CI: 2.26 to
3.34)
3.2% (n = 108)
(95% CI: 2.6 to
3.79)
Acquisition rate⁄1,000 patient-days 4.4 4.9
Incidence rate ratio per 1,000 patients days at risk 0.90; 95% CI: 0.69 to 1.2
Unadjusted odds ratio 0.88; 95% CI: 0.52 to 1.46
Adjusted odds ratio 0.91; 95% CI: 0.61 to 1.34
MRSA infection
Pofahl[20] Universal screening with PCR Targeted
screening
Infection rate per 100 procedures 0.09 0.23
Infection rate per 100 procedures among patients undergoing
orthopedic surgery
0.00 0.03
Proportion of MRSA SSI 7.1% 11.6%
Robiscek[21] Universal surveillance with
PCR
Baseline (i.e., no
surveillance)
MRSA infections⁄10,000 patient-days -5.0 (95% CI: -6.6 to -3.5) 8.9 (95% CI: 7.6 to
10.4)
Change in MRSA infections from baseline to universal surveillance -69.6% (95% CI: -89.2% to -19.6%)
Change in MRSA bacteremia from baseline to universal surveillance per
10,000 patient-days
-1.1 (95% CI: -1.9 to -0.2)
Jeyaratnam[27] PCR Chromogenic
agar
Number of patients with wound infections 21 22
Odds ratio of wound infections 0.91; 95% CI: 0.48 to 1.7
Number of MRSA bacteremia cases 1 2
Odds ratio of MRSA bacteremia 0.49; 95% CI: 0.01 to 9.1
Jog[22] 12-months post MRSA
screening
12-months prior
to MRSA
screening
SSI rate 2.22% 3.30%
MRSA transmission rate
Jeyaratnam[27] PCR Chromogenic
agar
MRSA transmission rate 0.33 0.36
Incidence rate ratio 0.85; 95% CI: 0.64 to 1.12
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Turnaround time from admission to results reported
PCR Chromogenic
agar
Hombach[23] BD Gene Ohm
MRSA
Xpert MRSA
Median transport time (from collection to arrival at the laboratory) 4 hours and 25
minutes
4 hours and
25 minutes
4 hours and 25
minutes
Median collection time (includes administration and accumulation of
specimens to utilize the master mix to full capacity-for BD GeneOhm
only)
6 hours and 55
minutes
1 hour and 5
minutes
Directly inoculated
Median analysis time (includes DNA extraction for BD GeneOhm MRSA
and Gene Xpert)
5 hours and 40
minutes
2 hours and
20 minutes
54 hours and 30
minutes
Median time to reporting from sampling to reporting of test results 17 hours 7 hours and
50 minutes
68 hours and 50
minutes
PCR Chromogenic
agar
BD Gene Ohm
MRSA
Xpert MRSA
Wassenberg[23] Time from start of isolation to delivery of specimen to laboratory 8.2 hours (IQR: 1.3
to 17.0)
5.0 hours
(IQR: 1.0 to
16.6)
4.8 hours (IQR: 0.7
to 14.6)
Time from arrival in the laboratory to definite result 3.6 hours (IQR: 2.2
to 6.7)
2.0 hours
(IQR: 1.5 to
3.3)
Not reported
Laurent[17] PCR Chromogenic agar
Median turnaround time 1.9 hours (IQR: 1.4
to 4.2 hours)
66.9 hours (IQR: 50.9 to 67.9
hours)
Creamer[18] PCR Chromogenic agar
Mean overall turnaround time 13.2 hours 46.2 hours
Mean overall turnaround time for MRSA-positive specimens 17.1 hours (range:
2.0 to 75.8 hours)
53.9 hours (range: 26.0 to 123.8
hours)
Snyder; US; 2010
[19]
PCR Chromogenic agar
Average time to report MRSA-positive test results 17.4 hours (range:
4.12 to 31.1 hours)
28.1 hours (range: 13.9 to 49.6
hours)
Average time to report MRSA-negative test results 14.4 hours (range:
3.12 to 33.8 hours)
51.3 hours (range: 34.32 to 65.95
hours)
Hardy [25] PCR Chromogenic agar
Mean turnaround time 0.9 days 2.3 days
Aldeyab[26] PCR Chromogenic agar
Median time interval in surgical ward 19.3 hours
(IQR:13.8 to 23)
51.8 hours (IQR: 44.4 to 69)
Median time interval in medical/cardiology ward 22.7 hours
(IQR:19.8 to 23.8
hours)
42.2 hours (IQR: 40.3 to 69.6
hours)
Jeyaratnam[27] PCR Chromogenic agar
Median turnaround time 21.8 hours (IQR:
17.95 to 25.4)
46.4 hours (IQR: 39.1 to 66.1)
Isolation days
Wassenberg[23] PCR Chromogenic
agar
BD Gene Ohm
MRSA
Xpert MRSA
Time from definite test result to discontinuation of isolation 0.2 hours (IQR: 0
to 0.5)
0.3 hours
(0.2 to 0.5)
0.2 hours (0 to 0.5)
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Page 9 of 13study used Xpert MRSA and chromogenic agar, impacting
the median transportation across comparator arms. The
median transportation time was similar across all screen-
ing tests in another study,[24] but the analysis time was
the greatest with chromogenic agar (chromogenic agar =
54 hours and 30 minutes versus BD GeneOhm MRSA = 5
hours and 40 minutes versus Xpert MRSA = 2 hours and
20 minutes) [24]. The laboratory time was longer with BD
GeneOhm MRSA versus Xpert MRSA since the master
mix had to be filled to the capacity with specimens prior
to its use [23].
Isolation and open days
According to the study by Jeyaratnam et al., the number
of inappropriately isolated days (patients who were pre-
emptively nursed with MRSA precautions but were not
MRSA positive on admission) was lower in the PCR
arm compared with the chromogenic agar arm (277 ver-
sus 399), but the proportion of patients who were pre-
emptively isolated was similar between the comparison
arms (5% versus 4.7%) [27]. The number of inappropri-
ate open days (patients for whom isolation precautions
were not implemented and were MRSA positive on
admission) was 351 for screening with PCR and 389 for
screening with chromogenic agar [27].
According to Wassenberg et al., a shortened duration
of isolation in hours was observed with Xpert MRSA,
closely followed by BD GeneOhm MRSA. The duration
of isolation for chromogenic agar was also doubled
compared with Xpert MRSA (30.0 hours versus 16.1
hours) [23].
Discussion
Eleven studies on the clinical effectiveness of screening
with PCR versus screening with chromogenic agar or no
screening were included in our systematic review. Over-
all, MRSA colonization, infection, and transmission rates
were lower using PCR for screening versus chromogenic
agar, but the possibility of a null difference could not be
excluded based on the 95% CIs in most cases. One
study detected a decrease in the prevalence of MRSA
infection and bacteremia between universal screening
with PCR compared with no screening [21]. In addition
to placing colonized patients in isolation rooms,
attempts were made to decolonize them. Therefore, it is
difficult to discern the relative benefit of isolation com-
pared with decolonization using this strategy. Potential
biases that are related to study design may have affected
the outcome variables.
Harbarth et al [28]. conducted a prospective, interven-
tional cohort study using a crossover design to measure
the effect on MRSA infection rates in surgical patients at
admission, when universal screening is used. Standar-
dized infection control measures (for example, hand
hygiene) were compared with same-day multiplex in-
house PCR plus standardized infection control measures.
The results showed that same-day, universal screening
did not reduce the MRSA infection rate in large, surgical
wards compared with standardized infection control
measures (adjusted incidence rate ratio: 1.20; 95% CI:
0.85 to 1.69), suggesting that evidence in support of
MRSA universal screening at admission is inconclusive
[28]. The authors noted several limitations, including no
randomization of individual wards to receive interven-
tions, a passive post-discharge MRSA surveillance of
MRSA surgical site infection and no confirmation of
positive test results using PCR with culture-based meth-
ods. The authors also stated that most of these limita-
tions were resolved because of their crossover design
[28].
The turnaround time from admission to screening test
results being telephoned,[26,27] and the number of iso-
lation days were lower for screening using PCR com-
pared with screening using chromogenic agar,[27] but
the large discrepancies reported between the tests is sur-
prising since most chromogenic media are intended to
be read at 24 hours. Two studies observed the shortest
turnaround time with Xpert MRSA versus BD Gen-
eOhm MRSA and chromogenic agar [23,24]. Additional
factors that may influence the turnaround times are the
Table 2 Main Study Findings (Continued)
Time from start of isolation to definite test result 17.8 hours (5.0 to
24.2)
14.0 hours
(3.4 to 21.2)
31.9 hours (24.7 to
41.5)
Duration of isolation 19.7 hours (6.0 to
34.6)
16.1 hours
(4.0 to 24.7)
30.0 hours (24.2 to
43.0)
Jeyarathnam[27] PCR Chromogenic agar
Number of inappropriately isolated days 277 399
Open days
Jeyarathnam[27] PCR Chromogenic
agar
Number of inappropriately open days 351 389
IQR = Inter-quartile range; OR = Odds ratio; PWE = Patient ward episodes; SSI = Surgical site infection
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Page 10 of 13infrastructure of the laboratory (in-house or reference)
that will provide the service; prevalence rate of MRSA
in hospital setting and number of specimens that will be
processed; available laboratory hours; and the laboratory
staff on-hand to process the screening test [7,23,24].
Despite the lower turnaround time for screening with
PCR, two studies did not a find a significant difference
in the MRSA transmission and acquisition rates between
screening with PCR and screening with chromogenic
agar [26,27]. Other interventions, such as preemptive
isolation, may influence the transmission and acquisition
rates in a hospital setting [25]. One study compared the
diagnostic performance of chromogenic agar, BD Gen-
eOhm MRSA and LightCycler MRSA advanced for
patients in hospitals, nursing homes, extended-care facil-
ities, and dialysis units and medical staff [29]. The
authors reported that the lab technologist hands-on
time for an average test batch of 25 samples using
LightCycler MRSA advanced was 41 minutes compared
with 75 minutes for BD GeneOhm MRSA [29]. The
mean processing time was 118.5 ± 17.2 minutes for
LightCycler MRSA advanced versus 137.2 ± 28.7 min-
utes for BD GeneOhm MRSA [29].
Even though BD GeneOhm MRSA and Xpert MRSA
are PCR technologies, there are differences between the
two tests. First, Xpert MRSA is automated using the
Cepheid GeneXpertDx System, so screening can be per-
formed in various health care settings, such as clinical
laboratory or as point-of-care testing;[13] thus, poten-
tially reducing the turnaround time of MRSA coloniza-
tion identification [30]. Second, the screening test
method can be performed health workers in a clinical
laboratory or near the site of patient care [30]. The use
of BD GeneOhm MRSA involves batch processing and
is validated to run on the Cepheid Smart Cycler System,
which is typically done in a laboratory by a medical
technologist [31]. The turnaround time is approximately
72 minutes or less using Xpert MRSA compared with
t w oh o u r su s i n gB DG e n e O h mM R S A ,d e p e n d i n go n
the batch size [31]. Although four different types of
chromogenic agar were used across the studies, the clin-
ical findings compared with PCR tests were consistent
for all chromogenic agar tests.
The selection of studies and the corresponding quality
assessment in the current clinical review were con-
ducted independently by two reviewers to reduce the
risk of bias. Few studies were of very high quality. For
instance, the risk of confounding was greater among
studies measuring the clinical effectiveness of screening
using PCR with no randomization,[26] among studies
that did not describe potential confounders or whether
they were investigated,[21,26] and among studies that
failed to state if patients who were lost to follow-up
were taken into account [21,26].
Our systematic review provides insufficient evidence
on the clinical effectiveness of PCR for MRSA screening
in hospitalized patients according to the number and
quality of studies identified in the literature. The evi-
dence is scarcer for screening with Xpert MRSA. High-
risk populations were studied, and none of the selected
studies included a pediatric population. One important
question relates to the most cost-effective screening test
for MRSA in hospitalized patients. While this review did
not examine this issue in detail, the authors will assess
the cost-effectiveness of PCR tests versus chromogenic
agar in a hospital setting in a separate study.
Screening is only one component of a MRSA infection-
control program and it is difficult to accurately determine
its relative contribution to overall control. The preven-
tion of MRSA transmission includes measures such as
hand hygiene, use of disinfectants, topical antibiotics and
use of isolation procedures (consisting of the use of single
rooms and the use of gowns and gloves with or without
masks during all patient contact). Decolonization regi-
mens for patients with MRSA in their nares include topi-
cal mupirocin alone or in combination with orally
administered drugs (for example, rifampin in combina-
tion with trimethoprim-sulfamethoxazole or ciprofloxa-
cin) and antimicrobial soap for bathing. These treatments
are usually limited to MRSA outbreaks or settings with
high-prevalence [32]. Evidence is vague concerning the
influence of MRSA screening with PCR compared with
other infection control strategies or changes in infection
control policies on the MRSA transmission rates.
Although behaviors are a challenge to measure, future
studies with this focus may offer more comprehension
on the optimal infection control strategy for MRSA in a
hospital setting.
Conclusions
Our systematic review found small differences in the
MRSA colonization, infection, and transmission rates
between screening using PCR and screening using chro-
mogenic agar, but the turnaround time and number of
isolation days were lower for screening with PCR versus
screening with chromogenic agar. This difference was
the most pronounced with Xpert MRSA. To contain
MRSA transmission in the hospitals, factors such as the
number of contacts between healthcare workers and
patients, number of patients attended by one healthcare
worker per day, probability of colonization among
healthcare workers, and MRSA status of hospital shared
equipment and hospital environment must be
considered.
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